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Executive Summary Heart failure is a life-threatening disease and
addressing it should be considered a global health priority. At present, ap-
proximately 26 million people worldwide are living with heart failure. The
outlook for such patients is poor, with survival rates worse than those for
bowel, breast or prostate cancer. Furthermore, heart failure places great
stresses on patients, caregivers and healthcare systems. Demands on
healthcare services, in particular, are predicted to increase dramatically over
the next decade as patient numbers rise owing to ageing populations, detri-
mental lifestyle changes and improved survival of those who go on to de-
velop heart failure as the final stage of another disease.
It is time to ease the strain on healthcare systems through clear policy initiatives
that prioritize heart failure prevention and champion equity of care for all.
Despite the burdens that heart failure imposes on society, awareness of the dis-
ease is poor. As a result, many premature deaths occur. This is in spite of the fact
that most types of heart failure are preventable and that a healthy lifestyle can
reduce risk. Even after heart failure has developed, premature deaths could be
prevented if peoplewere taught to recognize the symptoms and seek immediate
medical attention. Public awareness campaigns focusing on these messages
have great potential to improve outcomes for patients with heart failure
and ultimately to save lives.
©2014 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
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Introduction
The prevention of disease and death due to heart failure
needs to be made a global health priority. Despite the
increasingly large numbers of people living with and
dying from heart failure, awareness of the disease is low
amongst the public, politicians and even some healthcare
professionals. Although there is no cure for heart
failure, many cases are preventable, and most patients
can be treated effectively to improve quality of life and
survival. Policymakers have a responsibility to ensure that
as many people as possible benefit from the available
measures for prevention, diagnosis, treatment and long-term
management of heart failure. At the same time, research
should be supported in areas in which there are urgent
unmet needs.
Compliance with clinical practice guidelines is also
associated with improved outcomes for patients with heart
failure. However, in many countries, there is considerable
variation in how closely physicians follow guideline
recommendations. To promote equity of care, improve-
ments should be encouraged through the use of hospital
performance measures and incentives appropriate to the
locality. To this end, policies should promote the research
required to establish an evidence base for performance
measures that reflect improved outcomes for patients.
Continuing research is essential if we are to address
unmet needs in caring for patients with heart failure.
New therapies are required for patients with types of
heart failure for which current treatments relieve
symptoms but do not address the disease. More
affordable therapies are desperately needed in the
economically developing world. International collabora-
tive research focusing on the causes and treatment of
heart failure worldwide has the potential to benefit tens
of millions of people.
Change at the policy level has the power to drive
improvements in prevention and care that will save lives.
It is time to make a difference across the globe by
confronting the problem of heart failure.
A call to action: policy recommendations. We urge
policymakers at local, national and international
levels to collaborate and act on the following
recommendations.
Promote heart failure prevention
• Support the development and implementation of
public awareness programmes about heart
failure. These should define heart failure in
simple and accessible language, explain how to
recognize the symptoms and emphasize that
most types of heart failure are preventable.
• Highlight the need for healthcare professionals
across all clinical disciplines to identify patients with
illnesses that increase the risk of heart failure and to
prescribe preventive medications.
• Prioritize the elimination of infectious diseases in
parts of the world where they still cause heart
failure.
Improve heart failure awareness amongst
healthcare professionals
• Encourage the development and use of heart fail-
ure education programmes for all appropriate
healthcare professionals. These should aim to im-
prove the prevention, diagnosis, treatment and
long-term management of heart failure and raise
awareness of clinical practice guidelines.
Ensure equity of care for all patients with heart
failure
• Provide a healthcare system that delivers timely
access to diagnostic services and treatment of heart
failure, as well as a seamless transition to long-term
management.
• Ensure that the best available and most appro-
priate care is consistently provided to all patients
with heart failure through efficient use of
resources.
Support and empower patients and their care-
givers
Provide resources for the education and practical
support of patients with heart failure and their families
or other caregivers, empowering them to engage
proactively in long-term care.
Promote heart failure research
• Fund and encourage international collaborative
research to improve understanding of the pat-
terns, causes and effects of modern day heart
failure and how the disease can be prevented
across the globe.
• Fund and encourage research into new and more
affordable therapies and medical devices for all
types of heart failure.
• Fund and encourage research into evidence-based
healthcare performance measures that reflect im-
proved clinical outcomes for patients with heart
failure.
Keywords Chronic heart failure; Acute heart failure;
Epidemiology; Therapy; Awareness
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An international approach is needed to identify the
most effective ways of addressing the problem of heart
failure in different parts of the world and to incorporate
the necessary measures into everyday practice. To this
end, the Heart Failure Association of the European Society
of Cardiology has launched the Global Heart Failure
Awareness Programme. Heart failure groups across the globe
will be involved in the programme to ensure sharing of
knowledge, experience and recommendations across
countries and continents.
This white paper is a core component of the inaugural
phase of the Global Awareness Programme. It examines
the worldwide burden of heart failure, highlights the
challenges of dealing with the disease and makes
evidence-based recommendations for policy change
(Figure 1). Policy initiatives at local, national and interna-
tional levels have the potential to reduce deaths due to
heart failure and improve quality of life for patients.
The global burden of heart failure
Heart failure is a serious condition in which the heart is
unable to pump enough blood to meet the needs of the
body. Although often life threatening, the typical symptoms
of heart failure (breathlessness, swollen limbs and fatigue)
are usually less dramatic than those associated with a heart
attack. In economically developed countries, up to one
person in five is expected to develop heart failure at some
point in their life1 and even more people will be affected
as family members, friends or healthcare professionals.
Patient perspective2
When you have heart problems, you always worry
[that] the next breath is your last one. That’s
something you never know.
Heart failure survival rates remain poor
across the globe
Across the globe, 17–45% of patients admitted to a hospital
with heart failure die within 1 year of admission and the
majority die within 5 years of admission (Figure 2).3–24
In recent years, survival rates for patients with heart
failure have improved in many parts of the world, in
parallel with the introduction of modern evidence-based
therapies and patient management systems.3,25–31
Nevertheless, about 2–17% of individuals admitted to a
hospital with heart failure die while in a hospital
(Figure 2). Survival rates are better for those treated in
outpatient clinics, who typically have less severe symp-
toms than those treated in a hospital.22,32 However, even
the latest therapies may only relieve symptoms in many
patients, without slowing the progression of their disease
or prolonging life.33,34 This is because heart failure can
arise from a number of different underlying problems
with the structure or function of the heart, some of which
are more difficult to treat than others (see Section on
Preventing Heart Failure in High-risk Groups).
Despite improvements in care over the past 20 years,
the outlook for patients with heart failure remains poor,
and survival rates are worse than those for bowel, breast
or prostate cancer.35–37
Heart failure is common, and patient
numbers are increasing
About 26 million adults worldwide are living with heart
failure,38 leading some to describe it as a global pandemic.39
In comparison, 32 million are living with cancer40 and 34
million with HIV/AIDS.41 In many countries, population-
based studies have found that about 1–2% of people have
The global burden of heart failure (Section 1)
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Figure 1 Heart failure: preventing disease and death worldwide.
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heart failure, and similar or higher proportions have been
reported in single-centre studies (Figure 3).4,8,9,11,42–46
Heart failure becomes more commonwith increasing age.
In North America and Europe, few patients with heart failure
are 50years of age or younger50–52 and more than 80% are
65years of age or older.38 The number of patients with heart
failure is predicted to increase in countries with ageing
populations.53 Japan, in particular, has the most rapidly
ageing population of all economically developed nations.54
In the USA, there were 5.8 million patients living with heart
failure in 2012, and this is expected to rise to 8.5 million by
2030.45 Another contributing factor to these increasing
numbers is the improvement in treating heart attacks and
other cardiovascular diseases that damage or place an extra
burden on the heart. More patients with these conditions are
surviving now than did in the past, but those who survive
are at high risk of going on to develop heart failure.39
In economically developing areas, such as parts of
Latin America and Asia, the numbers of patients with
heart failure are also increasing.55–58 The increase is
largely a result of the shift towards a Western-type life-
style and its associated diseases, for example, conditions
such as diabetes increase the risk of developing heart fail-
ure (see Section on Preventing Heart Failure in High-risk
Groups). This is despite reductions in the number of cases
caused by Chagas disease in urban areas of Latin Amer-
ica58 and reductions in the number of cases of Davies dis-
ease (a disorder in which the heart muscle becomes rigid)
in tropical areas.59
Infections remain a common cause of heart failure in
many parts of the world and can strike at any age. Heart
failure is not a disease of the elderly in sub-Saharan Af-
rica, where half of patients hospitalized with the disease
are 55years of age or younger.5 Patients in the Asia Pacific
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Figure 2 Death rates for patients hospitalized with heart failure across the globe.3–14,16–24,47,48 Each symbol represents data from a
published study. Vertical shaded areas show the range in reported death rates within each time frame. Horizontal shaded areas show
regions. The data categorized as ‘Europe’ is from the EuroHeart Failure Survey (24 countries),21 the EuroHeart Failure Survey II
(30 countries)23 and the ESC-HF pilot survey (12 countries).22 The data are not age adjusted.
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region also tend to be younger than those in Western
regions.60 Rheumatic fever due to preventable bacterial
infections is a prominent cause of heart failure in Africa,
Asia, Australasia and Latin America.61 HIV infection is also
a major contributor to heart-related disease across the
world.62 In areas of Latin America where Chagas disease is
common, nearly half of all heart failure cases are a direct
result of this preventable parasitic infection.63
In tropical areas, Davies disease has historically been a
common cause of heart failure. The underlying reasons for
the development of Davies disease have not been fully
established but candidates include childhood malnutrition,
dietary toxins and inflammation, aswell as infections. In the
Kerala region in south India in recent years, the number of
new cases of Davies disease has declined in parallel with
improvements in socioeconomic and health status.59
Heart failure exacts severe economic,
social and personal costs
Globally, the increasing burden of heart failure is taking
its toll on society, in particular on patients, caregivers
and healthcare systems.
As a primary diagnosis, heart failure accounts for about
1–4% of all hospital admissions in economically developed
countries (Figure 4).14,64–67 This is likely to be an under-
estimate because heart failure may be recorded as a
secondary diagnosis, or may even go unrecorded, espe-
cially in the large number of patients who have other
cardiovascular diseases.68 Country-wide information is
sparse in other regions,55 highlighting the need to set up
new national registries to quantify accurately the burden
of heart failure.
Caring for patients with heart failure comes at a high
economic cost and accounts for about 1–3% of total
healthcare expenditure in North America,69 Western
Europe70 and Latin America.58 In comparison, the total
global expenditure on all healthcare goods and services in
2010 was in the region of $6.5tn.71,72 In Germany, the
total medical costs attributable to heart failure were
estimated at €2.9bn in 2006. This figure includes costs
for inpatient, outpatient and day care services, as well
as drugs, devices and other medical products.70 In the
USA, the total hospital, physician, prescription and home
healthcare costs associated with heart failure were
estimated at $20.9bn in 2012 and are projected to rise
to $53.1bn by 2030.45 The 2012 figure is comparable with
Figure 3 Proportion of the population living with heart failure in individual countries across the globe.4,8,9,11,42–46a Heart failure or
swollen limbs. Estimates based on a single centre or hospital are indicated by an H. No population-based studies have reportedly been
conducted to estimate the proportion of the population living with heart failure in Africa49 or Latin America.13
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the annual capital spend required to ensure clean, safe
drinking water for the entire nation.73
The lengthy and repeated hospital stays that are
typically required by patients with heart failure account
for the majority of this economic burden.45,70 Across
the globe, the average length of hospital stay is about
5–10 days.3,5,6,11,12,14,19,20,24,43 Over the past two decades,
the length of stay has become shorter in Europe,
North America and Australasia.3,5,11,43 Nevertheless, in
Europe and North America, about a quarter of patients
admitted to a hospital with heart failure are readmitted
within a month and up to two-thirds within a year,
usually for recurrence of heart failure.11 Individuals
who are readmitted with worsening or recurrent
symptoms of heart failure are at a high risk of terminal
decline.74 Hospital readmission can improve survival
rates amongst patients with worsening heart failure;
however, identifying those for whom long-term monitor-
ing is a suitable alternative may be a more efficient use
of resources (Section on Future Directions in Care: Urgent
Unmet Needs).4
Heart failure markedly affects patients’ quality of life.
Fear, anxiety and depression are common,75 and work,
travel and day-to-day social and leisure activities are
difficult for those with breathlessness and extreme
fatigue.76 The emotional, physical and financial costs
are also high for caregivers looking after a family member
with heart failure.77
Patient perspective78
I’m not depressed… not really depressed… it’s just a
low feeling and it’s not a happy feeling, and you just
never feel your life’s worth anything at times.
Caregiver perspectives79
At night, when he’s lying in bed and I don’t hear
him breathe for a while, it gives me the nerves.
Then I start counting. And suddenly I hear him
breathing again. Then I think, oh dear, one morning
I will wake up and then he’s gone.I don’t mean to
complain but if you are used to going out and
now you have to stay home all the time, you know
all the time. My daughter lives around the corner
and I go out a lot with her, with the dog, to keep
my mind off things…I dare not stay away much
longer. My daughter wants me to come along to
go to the seaside and we will also take the dog with
us, but I am afraid to go. To go out for a whole day
is much too long.
Asia HF/total HF
Japan (2011) 1.24% 174 957
Korea (2011) 0.78% 57 147
Singapore (2011) No data 15 535
Middle East HF/total HF
Israel (2010) 1.31% 19 707
FHlatot/FH
Europe (22 countries) 0.32–3.73% 
France (2010) 1.46% 159 143
Germany (2011) 1.54% 306 250
Poland (2010) 3.73% 229 328
UK (2011) 0.88% 73 790
Other 18 countries surveyed  626 185
Australasia  HF/total HF
Australia (2012)  1.38% 53 035
New Zealand (2011) 1.53% 9876
Africa HF/total HF
South Africa (2006) 0.65% No data
North America HF/total HF
Canada (2011)  1.76% 49 829
USA (2010) 3.04% 1 179 151
Latin America HF/total HF
Brazil (2013) 2.11% 235 692
Chile (2010) 1.70% 27 607
Mexico (2011) 1.64% 90 695
Figure 4 Proportions and numbers of hospital admissions with heart failure as the primary diagnosis in countries across the
globe.14,64–67 HF, number of hospital admissions with heart failure as the primary diagnosis; HF/total, hospital admissions with heart
failure as a primary diagnosis as a proportion of total hospital admissions. Data for South Africa are from a single cohort in Soweto.
aHF/total from 2010, the most recent year for which both data sets were available.
Addressing heart failure 9
©2014 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. ESC Heart Failure 2014; 1: 4–25
DOI: 10.1002/ehf2.12005
Heart failure causes large numbers of deaths and wide-
spread ill health and exacts huge economic and social
costs—and the problem is becoming worse. Now is the time
for coordinated public heart failure awareness programmes
and strategic and political initiatives to improve care across
the globe.
Preventing heart failure in high-risk
groups
Preventing heart failure is of paramount importance.
Once established, the deterioration in the heart’s condition
can often be treated but typically cannot be reversed.
Policymakers should highlight the need for healthcare
professionals across all clinical disciplines to identify
patients with illnesses that increase the risk of heart failure
and prescribe preventive medications. Equity of access to
preventive medications should be provided for those at
greatest risk of developing heart failure, regardless of age,
sex or income. Policymakers should also prioritize the
elimination of particular infectious diseases in parts of the
world where they still cause heart failure.
What causes heart failure?
The term ‘heart failure’ describes a situation in which a per-
son’s heart cannot pump enough blood around the body
but does nothing to explain why this condition arises.
The clinical picture is complex because there are many
possible causes of heart failure, and some are illnesses
in their own right (Figure 5). Many cases of heart failure
can be regarded as the end stage of other underlying
illnesses and could be prevented if patients with these
illnesses were identified and treated appropriately at an
earlier stage.80
The heart is a remarkably adaptable organ. To cope
with problems that increase the demands placed on it,
the heart muscle is able to remodel itself to maintain
output in the short term. However, if this remodelling
continues in the long term, it can lead to abnormalities
and eventually to heart failure. For example, pumping
activity may decrease and valves may malfunction as the
heart enlarges, dilates and stiffens. Sooner or later, these
changes will manifest as overt symptoms of heart failure,
unless the process of deterioration can be halted or
delayed.
For most patients with heart failure, quality of life
can be dramatically improved by therapies that relieve
symptoms. For many patients, modern evidence-based
medications or devices are available that slow or halt
the progress of heart disease and improve survival.
However, no therapies have been shown to prolong
life for nearly half of all patients—those who have
heart failure with preserved ejection fraction (HFPEF)
(Section on Future Directions in Care: Urgent
Unmet Needs).
HEART
FAILURE
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Figure 5 Common causes of heart failure. Adapted from Cowie et al., improving care for patients with acute heart failure: before, during
and after hospitalization, 2014,11 with permission from Oxford PharmaGenesis™ Ltd.
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How can heart failure be prevented?
The fact that treatment is not always effective in prolonging
life means that prevention of heart failure should be
prioritized by policymakers. This is particularly important
for groups at high risk of developing this condition. Many
people have existing illnesses that place them at risk of heart
failure. Healthcare professionals treating such patients
should adopt a broad approach that includes encouraging
positive lifestyle changes that reduce the risk of heart failure
(see Section on Improving Public Awareness of Heart Fail-
ure) and prescribing preventive therapies as appropriate.
Medications that control blood pressure, heart rhythm and
cholesterol levels are effective in preventing heart failure
in the large number of people who have conditions such
as high blood pressure, coronary heart disease, kidney
disease and diabetes.81 Pacemakers and heart valve replace-
ment can also prevent heart failure in the small number of
people who have particular heart rhythm or valve disor-
ders.82 The range of illnesses that predispose patients to
heart failure is extremely wide. Healthcare professionals
across all clinical disciplines should be educated to identify
patients with illnesses that increase the risk of heart failure
and prescribe preventive medications. This will ensure that
as many people as possible benefit from available therapies.
Patients receiving long-term preventive therapies need to
be assessed regularly at the cost of healthcare providers.81
In addition, those with chronic conditions, such as
coronary artery disease or Chagas disease, should be evalu-
ated periodically and monitored for changes to the heart.
Patients with breast cancer are another group who would
benefit from such monitoring. Several existing and new
cancer treatments are toxic to the heart,83,84 and it is impor-
tant for healthcare professionals to be aware of the need to
assess and manage the associated risks.85
Bacterial infections that cause heart disease have been
largely eliminated in economically developed countries,
owing to the use of antibiotics. In other regions, bacteria
and tropical parasites cause a substantial proportion of heart
failure cases, many of which could be prevented if appropri-
ate therapies were used.86–88 The potential benefits of policy
initiatives aimed at eliminating infectious diseases therefore
extend to preventing heart failure inmany parts of theworld.
In particular, continuing global efforts are warranted to
eradicate Chagas disease, building on the progress that has
been made in Latin America over the past two decades.89
Identifying and treating patients at risk
of developing heart failure
Preventive treatment could be started earlier by identify-
ing people with early signs of abnormal heart muscle
remodelling. Large-scale screening programmes, such as
those that have enabled earlier treatment for bowel, cervi-
cal and breast cancer, are unfortunately not possible be-
cause there is no simple diagnostic test for heart failure
(see Section on The Need to Apply Best Practice).90 Early
changes in the structure or function of the heart can be
detected using medical imaging technology; it is not prac-
tical, however, to perform these complex procedures in
the enormous number of individuals with illnesses that
lead to heart failure and certainly not in the general pop-
ulation.90 In the future, advanced genetic tests and statis-
tical modelling of at-risk groups may be available that
consider the multitude of potential causes of heart failure,
and these may allow specific individuals to be identified
for in-depth screening (see Section on Future Directions
in Care: Urgent Unmet Needs).82
Targeting preventive medications towards individuals
at greatest risk of heart failure could increase cost-
effectiveness, allowing more people to benefit. Further
research in these areas is ongoing and should continue
to be supported by public and private funds. In addition,
awareness programmes should be aimed towards
everyone with medical conditions that predispose to heart
failure. These should include education about the symp-
toms of heart failure and the benefits of positive lifestyle
changes. The same messages are important for public
awareness programmes (see Section on Improving Public
Awareness of Heart Failure).
Preventing heart failure in the elderly
and socioeconomically disadvantaged:
unique challenges
Preventing heart failure in the elderly is becoming a more
pressing healthcare priority as populations age.91 Heart fail-
ure is the most common reason for hospital admission in
people over 65 years of age in economically developed re-
gions (see Section on The Global Burden of Heart
Failure).3,11,92,93 Elderly patients hospitalized with heart
failure are mainly women.94 Although a number of studies
of heart failure patients have indicated that survival rates
are better in women than inmen, recent research has shown
that the long-term prospects for women are not as good as
previously thought.95 Initiatives aimed at improving heart
failure prevention should therefore include strategies for
reaching out to older people, particularly older women.
In economically developed countries, heart failure is
both more common and more likely to be the cause of
death in people with low socioeconomic status than in
the rest of the population.29,96 This is still the case after
adjusting for differences in age, medication use and the
proportion of people with other heart-related diseases.96
It has been suggested that housing stability, social
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support, substance abuse, language proficiency and dis-
tance to hospital may play a role.97 More elderly women
than men live alone and in poverty in the USA and often
lack the social support of their families or communities.
Social support can help people to seek medical attention
if symptoms emerge and to change their lifestyles to re-
duce the risk of heart failure (Section on Improving Public
Awareness of Heart Failure).98
In rapidly developing countries, governments face the
double challenge of prioritizing the elimination of infectious
diseases in resource-poor or rural settings whilst not
neglecting the diseases emerging in urban areas as a result
of a shift towards a Western-type lifestyle.57 That elderly,
isolated, female or poor people are amongst thosemost likely
to have heart failure has done little to raise the profile of the
disease. It is time to improve awareness of heart failure via
mass campaigns funded by governments and industry.
Improving public awareness of heart
failure
Large numbers of premature deaths occur through ignorance
of the causes and symptoms of heart failure. There is a press-
ing need for public awareness programmes that define heart
failure in simple and accessible language, explain how to rec-
ognize the symptoms and emphasize the need for urgent
medical attention. The other important messages are that
most types of heart failure are preventable, and a healthy life-
style can reduce risk. Policymakers should support the devel-
opment and implementation of public awareness
programmes focusing on these messages.
Public awareness of heart failure
symptoms is dangerously low
Delaying hospital treatment by as little as 4–6 h after
symptoms of heart failure appear can increase the chances
of death,99–101 yet patients typically do not seek treatment
for hours or even days after developing symptoms.102 Pub-
lic education about the symptoms of heart failure and the
need to contact a healthcare provider as soon as symp-
toms appear is essential to ensure that patients benefit
fully from the available therapies and care.
When asked what the reasons were for their delay in
seeking treatment, many patients who delayed for longer
than the average reported that they ‘did not think symp-
toms were heart related’ and that symptoms were ‘not that
severe at first’.103 In another large European survey, only
3% of the public were able to identify heart failure from a
list of typical symptoms, compared with 28% for heart
attack and 48% for stroke. Most patients wrongly regarded
heart failure at not serious or as a normal consequence of
ageing.104 In low-income and middle-income countries
such as Indonesia, patients may not seek treatment straight
away because they live far from a hospital or lack health
insurance, but ignorance of heart failure symptoms is also
a major reason for delay.12 Another factor is depression,
which affects 20–40% of patients with heart failure. A de-
lay of more than 72h between the appearance of heart fail-
ure symptoms and hospitalization is reportedly more than
twice more likely in patients with depressive symptoms
than in those without.105 This underscores the need for
public awareness programmes to be combined with social
support initiatives for those most at risk.
Patient perspective2
I did at times start having queasy feelings and pains in
my one side, and it happened once or twice when driv-
ing. I pulled off the road, but I didn’t do anything about
it. All of a sudden, I was developing sleep apnea or
wasn’t breathing right but sloughed it off until I could
hardly breathe at all the last few days. I did ignore the
original symptoms. The last day, I woke up and couldn’t
breathewell and toldmy kid to getme to the hospital. I
was unconscious when I got to the hospital.
A healthy lifestyle reduces the risk of
heart failure
Cost-effective awareness, education and support programmes
to reduce the risk of heart failure should be at the forefront
of public health directives.90 Lifestyle interventions
could have substantial power to improve world health,
because obesity, diabetes, cigarette smoking and high
blood pressure all dramatically increase the likelihood
of heart failure.90 In the USA alone, it has been
estimated that a 30% reduction in the proportion of
people classed as obese would prevent about 44 000
cases of heart failure every year, with an annual saving
of nearly $500m in healthcare expenditure.106
Similarly, it has been estimated that a 5% reduction
in the number of people with diabetes in the USA
would prevent about 30 000 heart failure cases every
year.107 Being severely overweight has been shown to
double the risk of heart failure and smoking to increase
it by about 50%.38
It is a sad fact that our improved understanding of these
risk factors has not prevented an explosion in the numbers
of people who are obese or who have diabetes or high
blood pressure. Renewed commitment to public educa-
tion about the importance of healthy diet and weight, reg-
ular exercise and avoiding smoking should be a priority
for policymakers.
In low-income and middle-income countries, lifestyle-
based interventions to prevent heart failure have been
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calculated to be more cost-effective than pharmaceutical
interventions.108 The urgent need to address lifestyle risk
factors globally is recognized by the United Nations,109
including in regions such as sub-Saharan Africa, where
non-infectious diseases associated with a Western-type
lifestyle are not yet the leading causes of death or ill-
ness.110 Given the already increasing numbers of patients
with heart failure in economically developing regions,
governments should be encouraged to combine lifestyle-
based preventive measures with their programmes for
tackling famine and pestilence.111 Regulating the aggres-
sive marketing of high-calorie processed food by larger
global corporate businesses, especially to school children
and teenagers, could be considered.
The need to apply best practice
Compliance with clinical practice guidelines is often
associated with improved outcomes for patients with
heart failure. However, in many countries, there is
considerable variation in how closely hospitals follow
the national guideline recommendations for heart
failure. In response, policymakers should champion
equity of care for all patients. First, it is important to
encourage heart failure education programmes that
raise awareness of guidelines amongst all appropriate
healthcare professionals. Second, improvements in care
should be encouraged through the use of performance
measures and incentives appropriate to the locality.
Funding is needed for research into evidence-based
healthcare performance measures that reflect improved
clinical outcomes for patients with heart failure. By
driving improvements in care, policymakers can provide
a healthcare system that delivers timely access to
diagnosis and treatment of heart failure, followed by a
seamless transition to long-term management.
Guidelines worldwide agree on the key
stages in heart failure care
Clinical practice guidelines aim to help healthcare
professionals make evidence-based decisions about the
care of individual patients. Guidelines have been
published by many governmental and professional bodies
across the globe (Figure 6).58,63,80,112–124 Each of these
aims to summarize and evaluate the available evidence
for using particular medical interventions for particular
patients. Guidelines may differ, though, in what evidence
is included, how it is assessed and whether an interven-
tion is considered appropriate for care in the relevant
country or region.
The published guidelines therefore make different
specific recommendations, but all agree that there are
three essential stages of care for patients with heart failure:
• Diagnosis should be timely and accurate.
• Treatment should be appropriate to each patient and
available urgently, if necessary.
• Long-term management should include follow-up,
monitoring and support.
Smooth transitions between these stages are also
crucial for ensuring that patients with heart failure are
managed optimally throughout their healthcare journey.
Depending on the severity of their symptoms and the
services and facilities available in their communities,
patients can follow many different and complex pathways
through healthcare systems (Figure 7).11 Best practice
involves a seamless system of care that embraces both
hospital and community.
International consensus recommendations could help
to identify the best ways to improve practice in
diagnosis, treatment and long-term management. For
example, although the published guidelines agree on
which diagnostic tools are useful, they disagree on
which should be used for all patients with suspected
heart failure and in what order.125 A consensus recom-
mendation leading to greater clarity about best practice
should be encouraged, with endorsements from
credible local bodies.
Best practice in heart failure care
involves compliance with guidelines
Survival rates increase and readmission rates fall when
patients with heart failure are cared for in hospitals
that comply with clinical practice guidelines.126–128
Nevertheless, considerable variation in the quality
of heart failure care and clinical outcomes between
different hospitals has been demonstrated in several
countries.46,129–132 Before discussing ways of encouraging
compliance with guidelines, this section presents evidence
to show that there is room for improvement at all three
stages of heart failure care.
Best practice in diagnosis requires appropriate facilities
and knowledge
Diagnosing heart failure can be challenging, even for
trained professionals. Not all patients with heart failure
have the typical symptoms, and the same symptoms
can be experienced by patients who do not have heart
failure. Making an accurate diagnosis requires a range of
diagnostic tools and information, in conjunction with clin-
ical judgement and expert knowledge (Figure 8).
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Not all hospitals and care centres have a full range of
diagnostic tools available, especially in resource-poor
settings.111 Furthermore, even when facilities are avail-
able, they are not always used. For example, all published
guidelines agree that diagnosis should involve ultrasound
imaging to assess heart function, but 10–25% of patients
admitted to hospital with a primary diagnosis of heart
failure in Europe and the USA do not undergo
ultrasonography.133
Many patients are not initially seen by an expert in
heart failure because of where they enter the healthcare
system. Those with severe symptoms, such as breath-
lessness at rest, are most often assessed by paramedics
or emergency doctors in hospital, whereas those with
less obviously life-threatening symptoms are likely to
go to their family doctor or an outpatient clinic
(Figure 7). Education programmes are needed to raise
awareness of clinical practice guidelines amongst
healthcare professionals from a wide range of specialties
who may be the first to encounter patients with undiag-
nosed heart failure.
All suitable patients should receive recommended
evidence-based therapies
All published guidelines recommend the use of modern
evidence-based medications and devices that have
been shown to benefit patients with heart failure.
For example, there are medications that have been
shown to improve survival in patients who have left
ventricular systolic dysfunction (LVSD).80 LVSD is
weak pumping activity in the compartment of the
heart that supplies blood to the body; it occurs in
about half of patients with heart failure. In patients
with heart rhythm problems, and in some patients
with LVSD, implanted devices that continuously moni-
tor the activity of the heart and automatically deliver
the right type of electrical stimulation can dramatically
improve survival.80
Despite clear recommendations regarding evidence-
based medications, many patients with heart failure
do not receive a prescription for potentially beneficial
medication, because prescribers do not always
comply with the guidelines. In a survey of hospital
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Figure 6 Clinical practice guidelines for heart failure across the globe.58,63,80,112–124 ACCF, American College of Cardiology Founda-
tion; AHA, American Heart Association; DEGAM, Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (German College
of General Practitioners and Family Physicians); CCS, Canadian Cardiovascular Society; ESC, European Society of Cardiology; HAS,
Haute Autorité de Santé (French National Authority for Health); HeFSSA, Heart Failure Society of South Africa; HFSA, Heart Failure
Society of America; JSC, Japanese Circulation Society; MoH, Ministry of Health; NHFA, National Heart Foundation of Australia; NICE,
National Institute for Health and Care Excellence; SBC, Sociedade Brasileira de Cardiologia (Brazilian Society of Cardiology); SIGN,
Scottish Intercollegiate Guidelines Network.
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discharges in the USA, more than a quarter of patients
with heart failure who should have been given appro-
priate medication did not receive a prescription.127 In
Europe, prescription rates for recommended medica-
tions are also low, and when they are prescribed, the
doses specified are often below those recom-
mended.128,134 In Africa, the available information
indicates that fewer than half of patients admitted to
hospital with heart failure receive preventive medica-
tions, and a specific combination of drugs shown to
be effective in African Americans is seldom used.5
There is scope for policymakers to incentivize improved
prescribing of evidence-based medications to suitable
patients.
Guideline recommendations for heart failure medica-
tions are based on evidence from clinical trials conducted
mainly in Europe and the USA.80 In other parts of the
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world, the underlying causes of heart failure vary, and it is
not safe to assume that medications will be equally
effective in all patient populations. Further clinical
research to investigate the effectiveness of heart failure
medications in different groups of patients across the
world should be supported.135
Long-term patient management is as important as
diagnosis and treatment
Diagnosis and initial treatment mark only the start of the
healthcare journey for a patient with heart failure.
Guidelines recommend a seamless transition to a
management programme for long-term care that
incorporates follow-up, monitoring and support. How-
ever, surveys have reported that most hospitals in the
USA had fewer than half of 10 key recommended
practices in place and fewer than 3% had all 10 in
place.136 In Europe, only 7 of 26 countries reported
having heart failure management programmes in more
than 30% of their hospitals.137 Even when in place, such
programmes are not always used.138 As well as hospitals,
community heart failure clinics and specialist nursing
services have important roles to play in the long-term
management of patients (see Section on Future
Directions in Care: Urgent Unmet Needs). Uptake of
recommended management practices should be encour-
aged alongside initiatives to improve diagnosis and
treatment of patients with heart failure.
Encouraging compliance: measuring
and improving quality of care
Measuring performance and incentivizing improvement
are key parts of bringing patient care into line with guide-
lines. Policymakers need to be aware, however, that not
all performance measures currently in use necessarily re-
flect improved clinical outcomes for patients with heart
failure.139 As well as recording survival and rehospitaliza-
tion rates of patients with heart failure, an ideal measure
would also capture how efficiently resources are used.11
Performance measures should be tailored to reflect local
circumstances, particularly in low-income and middle-
income countries where it would be unrealistic to offer
every potentially beneficial therapy.140
Audits, registries and professional initiatives
Audits enable quality of care and outcomes for patients to
be compared, so that informed, evidence-based improve-
ments can be made. For example, the UK’s annual
National Heart Failure Audit collects information about
every adult hospitalized with heart failure in England
and Wales. Examples of success include a hospital that im-
proved its heart failure inpatient survival rates from 77%
(below average) to above average (94%) by introducing
a specialist heart failure team. Another hospital improved
survival of inpatients with heart failure (from 87% to
92%) and reduced 30 day readmission rates (from 24%
to 15%) by increasing compliance with several guideline
recommendations for diagnosis, treatment and long-term
management.46
Registries are the main source of real-world data on
severity, causes, treatment, long-term management and
outcomes for patients hospitalized with heart failure.
They are less comprehensive than audits, because they
do not attempt to include every patient. Although the ma-
jority of registries are set up only to collect data, it has
been suggested that the feedback provided by the
benchmarked reports produced by some registries can
lead to improvements in guideline adherence. For exam-
ple, both the use and the prescription at discharge of
drugs that control heart rate increased by about 30% over
the 3 years that data were submitted to the first major reg-
istry of patients with heart failure (the ADHERE registry
in the USA).39
To date, most data collected in registries is from North
America or Western Europe; however, the underlying
causes of heart failure are different in other parts of the
world. Heart failure registries therefore need to be set
up in more regions to improve global understanding of
how heart failure develops and how it can be prevented.
Country-level registries such as HEARTS in Saudi Arabia
(the first in an Arab population)24 and CHART-2 in
Japan141 have already contributed to the overall picture,
and the major multi-national GULF CARE and ASIAN-HF
registries have now been established in the Middle East
and Asia, respectively. Each of these multi-country data-
bases is set to contain information on approximately
5000 patients, and results of the first analyses from the
GULF CARE survey are expected shortly.
Professional initiatives can offer advice and support for
improving compliance with guidelines. For example, in the
USA, hospitals can join the ‘Get with the Guidelines—
Heart Failure’ programme run by the American Heart
Association. Hospitals sign up to use a performance im-
provement tool that records data and assists with decision-
making, and good performers receive public recognition. A
survey of hospitals taking part in the programme showed
that improved discharge and transitional care processes
reduced 30 day readmission rates for patients with heart
failure, although other strategies examined in the survey
were not associated with improved patient outcomes.142
Financial incentives and penalties
Improvements in hospital performance can be encouraged
by imposing financial penalties or offering financial re-
wards (known as ‘pay-for-performance’). For example,
hospitals in the USA have been obliged since 2001 to
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report on performance measures related to heart failure
care,143 and the Medicare budget of a hospital can be re-
duced if standards are not met. Many countries impose
penalties on hospitals for all readmissions within 30 days
of discharge. These penalties are designed to reduce pre-
ventable readmissions, but there is concern that they
may unfairly punish hospitals with good survival rates
and that they may in fact reflect variations in standards
of community care after discharge rather than care in a
hospital.144 Incentives for good performance can also be
offered outside of hospitals. For example, in the UK,
primary care physicians can sign up to the Quality and
Outcomes Framework,145 which includes heart failure in-
dicators, targets and payment points.146
Care pathways
Compliance can be encouraged through the use of care
pathways, which are guideline-based systematic plans
for the care of particular patients over a specific time pe-
riod. Care pathways have been shown to improve survival
amongst hospital patients with heart failure, but there is
no ‘one size fits all’ pathway suitable for use in all
healthcare organizations.147 Acute heart failure care ‘bun-
dles’ are being adopted in Scotland. These short checklists
focus on improving diagnosis (via expert review), improv-
ing treatment (via evidence-based prescription) and im-
proving long-term management (via referral to a heart
failure nurse service); initial results show promise in im-
proving survival rates.148
What are the implications for policymakers?
I’mproving the performance of healthcare services by
providing incentives and management systems that
encourage compliance with guidelines is a powerful tool
for policymakers. It is not necessarily safe to assume,
however, that patients with heart failure will enjoy
longer life and a reduced chance of hospital readmission
as a result of even nominally successful performance
improvement programmes. Just as medications and
devices have to be tested in clinical trials to show that
they are effective and safe, it has been argued that man-
agement strategies should also be supported by robust
scientific evidence before they are mandated by organi-
zations that pay for healthcare.149
Policymakers should fund and encourage activities that
build an evidence base for driving improved care and out-
comes for patients with heart failure. There is a pressing
need for research into evidence-based healthcare perfor-
mance measures that reflect improved clinical outcomes
for patients with heart failure. In parallel, more wide-
spread data collection via audits or registries should be
implemented where country-level initiatives are not al-
ready in place.
Future directions in care: urgent
unmet needs
There are urgent unmet needs at all stages of heart failure
care (Figure 9).
In addition to the policy measures discussed in previous
sections, it is crucial to support international collaborative
research into the causes, diagnosis, treatment and long-
term management of heart failure across the globe. In
economically developing nations, there is both a desper-
ate need and a growing market for affordable therapies.
Industry should be encouraged to take up this opportu-
nity. Policymakers can also make a substantial difference
by encouraging seamless transitions to long-term manage-
ment. Resources should be provided for the education
and practical support of patients with heart failure and
their families or other caregivers, empowering them to en-
gage proactively in managing long-term care.
Diagnosis: improved tools for medical
decision-making in heart failure
Blood tests exist that are useful for ruling out a diagnosis
of heart failure, but they cannot positively identify pa-
tients who do have heart failure.80 Diagnosis therefore re-
mains complex and relies on the clinical judgement of an
experienced healthcare professional (Section on The Need
to Apply Best Practice). A new specific and sensitive blood
test could make diagnosis of heart failure quicker, easier
and more accurate. A suitable blood test could also enable
large numbers of people to be screened for early signs of
heart failure (Section on Preventing Heart Failure in
High-risk Groups). Continued support is warranted for ba-
sic scientific research aimed at discovering the molecular
signatures in the blood of different types of heart failure.
In the future, statistical methods known as risk stratifica-
tion could be used to identify patients who need treatment
most urgently.150 Patients have a high risk of dying from
heart failure if they are admitted to hospital with very high
or very low blood pressure, low blood oxygen levels, poor
kidney function or a history of coronary heart disease.
However, assessing any of these parameters in isolation
is not accurate enough to drive decisions about a
patient’s care. Risk stratification involves entering several
parameters into a statistical model to generate a profile
of the treatment and follow-up most suitable for an indi-
vidual patient. This has the potential to improve efficiency
by enabling high-risk patients to be identified for intensive
treatment in hospital, whilst others are safely discharged
or treated as outpatients.150 Further development of risk
stratification methods to make them suitable for wide-
spread adoption should be supported.
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Treatment: new options are needed for
many patients with heart failure
Although symptoms can usually be relieved, modern
heart failure therapies do not prolong life in about half
of all patients. New therapies are needed for patients
who have HFPEF (refer to the succeeding texts for a
description), acute heart failure, advanced heart failure
and certain heart muscle disorders. This highlights the
need for policymakers to encourage international col-
laborative research to improve the understanding of
how heart failure develops and how it can be
prevented. Additionally, more affordable therapies are
required for the huge market in the economically de-
veloping world.
Heart failure with preserved ejection fraction
Nearly half of patients with heart failure have a form of
disease known as HFPEF. Although symptoms can be con-
trolled, no treatment has yet been shown to improve sur-
vival in patients with HFPEF, and death rates have
remained unchanged over the past 20 years.151 Unlike
most patients, those with HFPEF have no obvious reduc-
tion in the proportion of blood pumped out of the cham-
ber of the heart that supplies blood to the body (the
ejection fraction),33 and many of them are elderly women
with a history of high blood pressure.34 HFPEF is a gen-
eral term used to describe patients who probably have a
variety of underlying diseases, despite all having similar
symptoms. This has made it particularly difficult to find
effective therapies to treat HFPEF and highlights the need
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for more basic research into its causes.151 Governments
and industry should continue to support the testing of
existing medications in large-scale clinical trials and the
development of new drugs for the treatment of HFPEF.
Acute heart failure
Patients with acute heart failure experience a rapid
worsening of symptoms, which often leads to emergency
hospitalization. Therapies for acute heart failure have
generally changed little over the past two decades, de-
spite ongoing research.11 Options are limited to drugs that
relieve breathlessness and reduce fluid build-up by in-
creasing urine production or dilating blood vessels. Drugs
that act directly on the heart muscle to increase the force
of contractions can have adverse effects and are used only
in critically ill patients when the oxygen supply to vital or-
gans is dangerously low. None of these medications does
anything to address the underlying cause or causes of
heart failure, leaving patients at a high risk of death after
discharge from a hospital.152 Despite the difficulties of
conducting clinical research in an emergency setting, gov-
ernments and industry should continue to support devel-
opment of new medicines for treating acute heart failure.
Advanced heart failure
As a weakening heart tries to maintain its function, the
adaptive remodelling changes in the heart muscle initially
maintain heart output but eventually lead to a vicious
cycle of worsening heart failure as the heart becomes
more and more abnormal. Patients in this debilitating
stage of the disease are usually repeatedly hospitalized
for recurrent episodes of acute heart failure, any one of
which could result in death. For patients with worsening
HFPEF, nothing can currently be performed to slow
their decline.
In the past, clinical trials have focused on treating heart
failure either during a single hospital admission or outside
a hospital. The unique features of patients with advanced
heart failure mean that clinical trials need to extend
beyond a single hospital admission. Encouraging such
research would provide evidence to support the use of
current and new therapeutic options in this group of
extremely vulnerable patients.153,154
Patients who have heart failure and other diseases
Many patients with heart failure also have other medical
conditions, such as kidney disease, lung disease or diabe-
tes. These illnesses are particularly common in individuals
with heart failure who are elderly or have been hospital-
ized.155 Many heart failure medications may not be suit-
able for patients who also have other medical conditions.
This is because the drugs used to treat different diseases
may interfere with one another, or a drug suitable for
treating one disease may worsen the other.80 New
therapies are usually tested in young patients who have
only heart failure, but they may not have been shown to
work in the real world, where many patients have several
overlapping diseases.133 This underscores the need to sup-
port basic clinical research into the underlying diseases
that lead to heart failure so that new therapies can be
tested in specific groups of patients most likely to benefit.
Heart failure during and after pregnancy
Worldwide, an increasing number of women are recog-
nized as having heart problems when they become preg-
nant. Symptoms of heart failure can appear during the
last month of pregnancy or within a few weeks of giving
birth. There is a need to build an evidence base to support
recommendations about how to prevent and treat this
complex condition, especially in economically developing
countries.156
Overlooked heart muscle disorders
Some patients in Africa have specific types of irreversible
heart muscle disease that are not known to occur else-
where and are very poorly understood.157 Heart muscle
disorders that are uncommon in the rest of the world have
also been identified in Japan.57 Furthermore, there is no
evidence base for treating heart failure caused by Chagas
disease, and the causes of Davies disease are still not un-
derstood. The scope of heart failure research therefore
needs to extend beyond the causes of disease that are
common in Western countries.
Affordable heart failure therapies
The costs of caring for an individual patient with heart
failure have increased substantially over the past three de-
cades as new therapies have been proved to be effective.
However, it is unrealistic for healthcare systems in all
parts of the world to offer every potentially beneficial
evidence-based therapy.140 As well as ensuring that re-
sources are used efficiently and cost-effectively,
policymakers should fund research into more affordable
therapies and medical devices for the huge market in the
economically developing world.
Long-term management: innovation
could save lives and money
In most patients, heart failure is a long-term disease that
involves one or more episodes of hospitalization. New
strategies for long-term monitoring and management of
patients outside a hospital may improve quality of life
and survival rates while reducing the number and fre-
quency of readmissions.
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New approaches to long-term management outside a
hospital
Remote monitoring could help to identify life-threatening
deterioration that requires patients to return to a hospital
rapidly. It could also allow individuals to leave hospital
earlier than at present, without placing them at extra
risk.158 Technologies being tested include telemonitoring
devices (some of which are surgically implanted) and
telephone support (either automated or person to
person).159 Despite the promise of these approaches, it is
not yet clear whether they improve survival.160 Policymakers
should encourage more research before recommending
telemonitoring.
Care by specialist clinics or teams after discharge from
hospital has been shown to increase survival rates
amongst patients and to deliver cost savings by reducing
hospital readmissions.161,162 Community clinics special-
izing in heart failure can provide patients with access
to teams of healthcare professionals and up-to-date diag-
nostic facilities and therapies outside hospital. Specialist
nurses are key members of such teams and are instrumental
in delivering long-term care.163 It is not the location but the
quality of care that produces results, and healthcare pro-
viders should be aware that new community clinics are most
likely to benefit patients when they complement existing
hospital services.
Palliative care services aim to improve quality of life for
patients and their families through a holistic approach
that addresses psychological, social and spiritual needs.
This type of approach can play an important role in facil-
itating emotionally difficult discussions between patients
and healthcare professionals. However, at present only a
minority of patients with heart failure are referred to
palliative care services.164 Incorporating palliative care
into management pathways could aid decision-making
by improving communication between healthcare profes-
sionals, patients and their families.11
The importance of encouraging patient self-care
Any programme aimed at improving long-term manage-
ment should recognize that patients with heart failure have
a key role to play in their own care. Self-care comprises
maintenance, monitoring and management (Figure 10).
Maintenance involves taking medication as prescribed,
exercising regularly and eating a healthy diet. Monitoring
involves keeping watch on symptoms and weight (which
can provide a warning sign of increasing fluid accumula-
tion). Management involves responding to changes in
symptoms, by adjusting doses of certain medications if they
have been prescribed for ‘use as needed’ (e.g. drugs that
increase urine production to reduce fluid accumulation),
or by seeking medical attention if symptoms worsen.165
A worldwide survey has revealed the need to improve
patient self-care. Most patients reported taking their
medication as prescribed but few reported monitoring
their weight or taking exercise regularly.166 Education
programmes are a priority but need to be designed carefully
because patients with greater knowledge of heart failure
have been reported to be more likely to delay seeking treat-
ment.167 This may reflect false optimism and a lack of
understanding that controlling the symptoms of heart
failure does not slow the progression of the disease. The
education medium also needs to be considered carefully.
Short video clips, text messages and social media could be
used to deliver simple but accurate messages. With 6 billion
people now estimated to own a mobile phone,168 technol-
ogy may provide an important way of reaching the remote
and socioeconomically disadvantaged.
Educating people about how to support a partner,
family member or friend with heart failure is also an im-
portant part of promoting self-care. Patients are more
likely to engage in beneficial self-care behaviours if they
have someone to help them than if they are socially
isolated. This emphasizes the need to improve community
support for socioeconomically disadvantaged patients and
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Sustaining physical and
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Figure 10 The three components of patient self-care.165 Reproduced from Cowie et al., improving care for patients with acute heart
failure: before, during and after hospitalization, 2014,11 with permission from Oxford PharmaGenesis™ Ltd.
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those who live alone.169 Policymakers should provide
resources for the education and support of individuals
with heart failure and their caregivers, empowering them
to engage proactively in managing long-term care.
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